Joint venture aims to enable early detection of eye diseases and prevent vision loss.
Boehringer Ingelheim and Zeiss Medical Technology a strategic collaboration to develop predictive analytics to enable early detection of eye diseases and prevent vision loss. As a dual effort, the companies plan to bring together their mutual backgrounds in ophthalmological technology, data analytics, algorithms, and the development of treatments to detect early and treat retinal diseases.
According to a company press release, the organizations intend to implement Zeiss’ cloud-connected devices and AI-assisted analysis of its extensive image data sets, providing a basis for clinical studies.
“Our partnership with Zeiss will allow us to develop precision therapies delivering the right treatment for the right patient at the right time to prevent vision loss by intervening before irreversible damage occurs. It is part of our commitment to champion early detection and treatment and will contribute to transforming the lives of people with serious eye disease,” said Ulrike Graefe-Mody, PhD, head of retinal health, Boehringer Ingelheim.
Reference: Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss. Boehringer Ingelheim. October 2, 2023. Accessed October 3, 2023. https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/boehringer-and-zeiss-partnership-eye-diseases
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.